T+AiTM (testosterone/anastrozole) / Havah Therapeutics - LARVOL DELTA

Havah Therapeutics Announces the Filing of a Patent Application Relating to the Use of HAV-088 for Reducing Tumor Size and Conserving Breast Tissue (Businesswire) - "Havah Therapeutics...announces the filing of a new provisional patent application directed to the use of HAV-088 for treating Ductal Carcinoma In-Situ....Backed by human in vivo data demonstrating on-target effect, the patent application covers the potential application of HAV-088...in treating hormone receptor positive (HR+) disease."

Patent • Breast Cancer

Havah Therapeutics to Present Real World Data at the RiseUp for Breast Cancer Conference (Businesswire) - "Havah Therapeutics...announced that the company will present real world patient data at the upcoming RiseUp for Breast Cancer Conference. The presentation will demonstrate the therapeutic potential of Havah’s novel combination implant therapy - of testosterone plus the aromatase inhibitor anastrozole - in agonizing the androgen receptor and inhibiting pathogenic pathways known to be involved in high risk breast tissue."

Real-world • Real-world effectiveness • Breast Cancer • Oncology • Solid Tumor